Keywords: UK, NICE, Celgene, Janssen Cilag, J&J, Sanofi-Aventis Multaq, Velcade, Thalidomide

Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF

Article | 27 August 2010

Print This

In what has been a busy week for the agency, draft guidance published yesterday (26 August), by the UK National Health ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in